JP2014529610A5 - - Google Patents

Download PDF

Info

Publication number
JP2014529610A5
JP2014529610A5 JP2014527278A JP2014527278A JP2014529610A5 JP 2014529610 A5 JP2014529610 A5 JP 2014529610A5 JP 2014527278 A JP2014527278 A JP 2014527278A JP 2014527278 A JP2014527278 A JP 2014527278A JP 2014529610 A5 JP2014529610 A5 JP 2014529610A5
Authority
JP
Japan
Prior art keywords
antigen
binding portion
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014527278A
Other languages
English (en)
Japanese (ja)
Other versions
JP6281163B2 (ja
JP2014529610A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/051948 external-priority patent/WO2013028810A1/en
Publication of JP2014529610A publication Critical patent/JP2014529610A/ja
Publication of JP2014529610A5 publication Critical patent/JP2014529610A5/ja
Application granted granted Critical
Publication of JP6281163B2 publication Critical patent/JP6281163B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014527278A 2011-08-22 2012-08-22 クロストリジウム・ディフィシレ抗体 Expired - Fee Related JP6281163B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526031P 2011-08-22 2011-08-22
US61/526,031 2011-08-22
PCT/US2012/051948 WO2013028810A1 (en) 2011-08-22 2012-08-22 Clostridium difficile antibodies

Publications (3)

Publication Number Publication Date
JP2014529610A JP2014529610A (ja) 2014-11-13
JP2014529610A5 true JP2014529610A5 (https=) 2015-10-15
JP6281163B2 JP6281163B2 (ja) 2018-02-21

Family

ID=47746848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527278A Expired - Fee Related JP6281163B2 (ja) 2011-08-22 2012-08-22 クロストリジウム・ディフィシレ抗体

Country Status (10)

Country Link
US (2) US9505847B2 (https=)
EP (1) EP2748194A4 (https=)
JP (1) JP6281163B2 (https=)
KR (1) KR20140078633A (https=)
CN (1) CN103917559B (https=)
AU (2) AU2012298877B2 (https=)
BR (1) BR112014004162A2 (https=)
CA (1) CA2845884A1 (https=)
SG (2) SG11201400916XA (https=)
WO (1) WO2013028810A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201400916XA (en) * 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
BR112014022240A2 (pt) 2012-03-09 2017-08-01 Csl Behring Ag composições compreendendo imunoglobulinas semelhantes à secretoras
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
WO2014144292A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
AU2015218909A1 (en) * 2014-02-19 2016-08-04 Emergent Biosolutions Canada Inc. Marburg monoclonal antibodies
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
AU2018298676A1 (en) * 2017-07-10 2019-12-19 Innate Pharma Siglec-9-neutralizing antibodies
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
CN112661849B (zh) * 2020-12-17 2022-05-20 杭州贤至生物科技有限公司 一种艰难梭菌重组蛋白单克隆抗体的制备方法和应用
WO2023113396A1 (ko) * 2021-12-14 2023-06-22 경북대학교 산학협력단 클로스트리듐 디피실 세균을 효과적으로 사멸시키는 재조합 항균 단백질의 용도
CN117720651B (zh) * 2023-12-13 2024-05-31 北京新兴四寰生物技术有限公司 抗艰难梭菌毒素b的单克隆抗体及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6096716A (en) 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
DK2270045T3 (en) 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
WO2006044643A2 (en) 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006071877A2 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US7790203B2 (en) 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
DK2368914T3 (en) 2006-03-10 2019-03-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
US7597891B2 (en) 2006-12-13 2009-10-06 Simon Michael R Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
JPWO2008114733A1 (ja) * 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Claudin−4抗体
UA104132C2 (en) * 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
EP2241578B1 (en) 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
US7740844B2 (en) 2008-04-29 2010-06-22 Taiwan Liposome Co. Ltd Anti-VEGF monoclonal antibody
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
US8986697B2 (en) 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
SG11201400916XA (en) * 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies

Similar Documents

Publication Publication Date Title
JP2014529610A5 (https=)
IL266756A (en) Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses
JP2022512132A5 (https=)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2012526558A5 (https=)
JP2016501877A5 (https=)
RU2016100892A (ru) Антитела против tweakr и их применение
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2018512138A5 (https=)
JP2009225799A5 (https=)
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
TW201134487A (en) Therapeutic DLL4 binding proteins
JP2011509245A5 (https=)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2016538318A5 (https=)
JP2013519364A5 (https=)
JP2022553922A5 (https=)
JP2012530487A5 (https=)
JP2012532851A5 (https=)
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
RU2011151287A (ru) АНТИ Notch-1 АНТИТЕЛА
JP2021511387A5 (https=)
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
RU2018106456A (ru) Антитело к epha4